Cargando…

Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study

BACKGROUND: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglycerid...

Descripción completa

Detalles Bibliográficos
Autores principales: Halcox, Julian P., Banegas, José R., Roy, Carine, Dallongeville, Jean, De Backer, Guy, Guallar, Eliseo, Perk, Joep, Hajage, David, Henriksson, Karin M., Borghi, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473961/
https://www.ncbi.nlm.nih.gov/pubmed/28623902
http://dx.doi.org/10.1186/s12872-017-0591-5
_version_ 1783244382137221120
author Halcox, Julian P.
Banegas, José R.
Roy, Carine
Dallongeville, Jean
De Backer, Guy
Guallar, Eliseo
Perk, Joep
Hajage, David
Henriksson, Karin M.
Borghi, Claudio
author_facet Halcox, Julian P.
Banegas, José R.
Roy, Carine
Dallongeville, Jean
De Backer, Guy
Guallar, Eliseo
Perk, Joep
Hajage, David
Henriksson, Karin M.
Borghi, Claudio
author_sort Halcox, Julian P.
collection PubMed
description BACKGROUND: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of high-density lipoprotein cholesterol. METHODS: This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease. RESULTS: Over 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy. CONCLUSIONS: A considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated. TRIAL REGISTRATION: The present study is registered with ClinicalTrials.gov (ID: NCT00882336). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12872-017-0591-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5473961
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54739612017-06-21 Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study Halcox, Julian P. Banegas, José R. Roy, Carine Dallongeville, Jean De Backer, Guy Guallar, Eliseo Perk, Joep Hajage, David Henriksson, Karin M. Borghi, Claudio BMC Cardiovasc Disord Research Article BACKGROUND: Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of high-density lipoprotein cholesterol. METHODS: This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease. RESULTS: Over 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy. CONCLUSIONS: A considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated. TRIAL REGISTRATION: The present study is registered with ClinicalTrials.gov (ID: NCT00882336). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12872-017-0591-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-17 /pmc/articles/PMC5473961/ /pubmed/28623902 http://dx.doi.org/10.1186/s12872-017-0591-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Halcox, Julian P.
Banegas, José R.
Roy, Carine
Dallongeville, Jean
De Backer, Guy
Guallar, Eliseo
Perk, Joep
Hajage, David
Henriksson, Karin M.
Borghi, Claudio
Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
title Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
title_full Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
title_fullStr Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
title_full_unstemmed Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
title_short Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
title_sort prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in europe: eurika, a cross-sectional observational study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473961/
https://www.ncbi.nlm.nih.gov/pubmed/28623902
http://dx.doi.org/10.1186/s12872-017-0591-5
work_keys_str_mv AT halcoxjulianp prevalenceandtreatmentofatherogenicdyslipidemiaintheprimarypreventionofcardiovasculardiseaseineuropeeurikaacrosssectionalobservationalstudy
AT banegasjoser prevalenceandtreatmentofatherogenicdyslipidemiaintheprimarypreventionofcardiovasculardiseaseineuropeeurikaacrosssectionalobservationalstudy
AT roycarine prevalenceandtreatmentofatherogenicdyslipidemiaintheprimarypreventionofcardiovasculardiseaseineuropeeurikaacrosssectionalobservationalstudy
AT dallongevillejean prevalenceandtreatmentofatherogenicdyslipidemiaintheprimarypreventionofcardiovasculardiseaseineuropeeurikaacrosssectionalobservationalstudy
AT debackerguy prevalenceandtreatmentofatherogenicdyslipidemiaintheprimarypreventionofcardiovasculardiseaseineuropeeurikaacrosssectionalobservationalstudy
AT guallareliseo prevalenceandtreatmentofatherogenicdyslipidemiaintheprimarypreventionofcardiovasculardiseaseineuropeeurikaacrosssectionalobservationalstudy
AT perkjoep prevalenceandtreatmentofatherogenicdyslipidemiaintheprimarypreventionofcardiovasculardiseaseineuropeeurikaacrosssectionalobservationalstudy
AT hajagedavid prevalenceandtreatmentofatherogenicdyslipidemiaintheprimarypreventionofcardiovasculardiseaseineuropeeurikaacrosssectionalobservationalstudy
AT henrikssonkarinm prevalenceandtreatmentofatherogenicdyslipidemiaintheprimarypreventionofcardiovasculardiseaseineuropeeurikaacrosssectionalobservationalstudy
AT borghiclaudio prevalenceandtreatmentofatherogenicdyslipidemiaintheprimarypreventionofcardiovasculardiseaseineuropeeurikaacrosssectionalobservationalstudy